Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
5.03 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Aldeyra Therapeutics, Inc. |
Symbool | ALDX |
Munteenheid | USD |
Prijs | 5.025 |
Beurswaarde | 299,236,740 |
Dividendpercentage | 0% |
52-weken bereik | 2.71 - 6.548 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Todd C. Brady M.D., Ph.D. |
Website | https://www.aldeyra.com |
An error occurred while fetching data.
Over Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)